首页|重组人脑利钠肽联合左西孟旦治疗急性心力衰竭患者的效果

重组人脑利钠肽联合左西孟旦治疗急性心力衰竭患者的效果

扫码查看
目的:探讨重组人脑利钠肽(rhBNP)联合左西孟旦治疗急性心力衰竭(AHF)患者的效果.方法:回顾性分析 2022 年1 月至 2023 年 5 月该院收治的 96 例AHF患者的临床资料,按照治疗方法不同将其分为对照组与研究组各 48 例.对照组采用左西孟旦注射液治疗,研究组在其基础上联合注射用rhBNP治疗.比较两组临床疗效、治疗前后心功能指标[每搏输出量(SV)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]水平、心肌损伤指标[肌酸激酶(CK)、脑钠肽(BNP)]水平、血流动力学指标[心率、平均动脉压(MAP)]水平及不良反应发生率.结果:研究组治疗总有效率为 93.75%(45/48),高于对照组的 79.17%(38/48),差异有统计学意义(P<0.05);治疗后,研究组MAP、SV、LVEF水平高于对照组,心率、LVEDD、LVESD、CK、BNP水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:rhBNP联合左西孟旦治疗AHF患者有利于提高临床疗效,增强心功能,减轻心肌损伤,改善血流动力学指标水平,效果优于单用左西孟旦治疗.
Effects of recombinant human brain natriuretic peptide combined with Levosimendan in treatment of patients with acute heart failure
Objective:To investigate effects of recombinant human brain natriuretic peptide(rhBNP)combined with Levosimendan in treatment of patients with acute heart failure(AHF).Methods:The clinical data of 96 patients with AHF admitted to this hospital from January 2022 to May 2023 were retrospectively analyzed.According to the different treatment methods,they were divided into control group and study group,48 cases in each group.The control group was treated with Levosimendan injection,while the study group was treated with rhBNP for injection on the basis of that of the control group.The clinical efficacy,the cardiac function indexes[stroke volume(SV),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]levels,the myocardial injury indexes[creatine kinase(CK),brain natriuretic peptide(BNP)],hemodynamics[heart rate,mean arterial pressure(MAP)]levels,and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 93.75%(45/48),which was higher than 79.17%(38/48)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of MAP,SV and LVEF in the study group were higher than those in the control group,the levels of heart rate,LVEDD,LVESD,CK and BNP were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:rhBNP combined with Levosimendan in the treatment of the AHF patients is helpful to improve the clinical efficacy,improve the cardiac function,reduce the myocardial injury and improve the levels of hemodynamic indexes.Moreover,it is superior to single Levosimendan treatment.

Acute heart failureRecombinant human brain natriuretic peptideLevosimendanCardiac function

刘岩

展开 >

郑州人民医院北院区急诊科,河南 郑州 450003

急性心力衰竭 重组人脑利钠肽 左西孟旦 心功能

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(8)
  • 13